Summary Somatic cells express genes that suppress telomerase activity and these genes may be inactivated in tumour cells. We postulated that cancer cells acquire immortality by activation of telomerase by the loss of such a gene. We have reported recently that a telomerase repressor gene may be located on 10p15.1 by deletion mapping using microcell-mediated chromosome transfer (MMCT), radiated microcell fusion (RMF), fluorescent in situ hybridization (FISH) and STS analysis. To independently confirm this result, we correlated expression of RNA component of telomerase (hTR) as a marker of telomerase expression by in situ hybridization with allelic loss in pulmonary carcinoid tumours. Unlike most malignant tumours, pulmonary carcinoids (which are low-grade malignant tumours) are heterogeneous for telomerase expression. Loss of 5 closely spaced polymorphic markers on 10p15.1, especially D10S1728, were highly correlated with hTR expression. In an additional experiment, 10p15.1 showed higher and more significant correlation than any region of 3p where it has been predicted as another chromosomal location of telomerase repressor with allelic loss of the region. Our findings strongly suggest that 10p15.1 harbours a gene involved in repression of telomerase RNA component in human somatic cells and each putative repressor (on 3p and 10p) may act independently.
Telomerase is an enzyme which adds repeated telomere sequences (TTAGGG) to chromosome ends and has an RNA component complementary to the telomeric repeat sequence (Moyzis et al, 1988; Zakian, 1989) . Its catalytic protein component synthesizes telomeric DNA directly onto the ends of chromosomes by the process of reverse transcription of the RNA template (Greider and Blackburn, 1989; Bhattacharyya and Blackburn, 1994; Feng et al, 1995; Kirk et al, 1997) . Telomerase activity has been detected in immortalized and tumour cells in vitro and in primary tumour tissues, most fetal tissues, and normal adult male reproductive cells and represents an important difference between normal somatic cells and cancer cells (Kim et al, 1994; Hiyama et al, 1995; Rhyu, 1995; Wright et al, 1996; Shay and Bacchetti, 1997; Sedivy, 1998) . Telomerase activity in lysates extracted from tumour cells and tumour tissues is not inhibited by mixture with cell lysates from normal cells, leading to the hypothesis that normal cells contain and express genes which repress the telomerase activity of tumour cells. One approach to map putative telomerase repressor genes to specific chromosomes is the identification of deletions in genome of telomerase-positive cells and tissues. We have previously reported that a senescence-inducing gene on normal human chromosome 3p represses telomerase activity in human renal cell carcinoma cells through downregulation of the catalytic subunit gene of human telomerase (hEST2/hTERT) (Koi et al, 1989; Shimizu et al, 1990; Ohmura et al, 1995) and, furthermore, the location of the telomeraserepressor gene has been narrowed to the 6 regions in 3p12-3p24.3 (Yashima et al, 1997; Mehle et al, 1998; Tanaka et al, 1998; Vieten et al, 1998; Cuthbert et al, 1999) . Of interest, Steenbergen et al revealed that the loss of heterozygosity (LOH) at either chromosome 3p or 10p loci correlated with the onset of telomerase activation during immortalization of human keratinocytes, raising the possibility that a gene on chromosome 10p also may function as a telomerase repressor. Moreover, loss of heterozygosity (LOH) on 10p has been observed in multiple human cancers such as gliomas, oesophageal carcinomas, and melanomas (Robertson et al, 1999) , prompting us to focus on this chromosomal arm. We recently presented evidence that a repressor for hTERT was located on 10p15.1 (between markers WI-4752 and D10S1728) (Nishimoto et al, 2001) .
We chose hTR expression as a marker of telomerase expression because hTERT shows relatively weak and unstable signals by in situ hybridization. To investigate the relationship between hTR expression and LOH we had to identify tumours which were heterogeneous for telomerase activity. While most tumours are strongly positive for hTR expression, we identified heterogenous 
MATERIALS AND METHODS

A mapping by LOH analysis using STS markers
Tumour specimens A total of 59 neuroendocrine lung tumours were collected from the files of the members of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). Histological slides were reviewed by WT, a pathologist familiar with the classification of neuroendocrine lung tumours, and the cases were categorized according to standardized histopathological criteria described previously. The case material consisted of 10 TCs, 11 ACs as low-malignant lung tumours (Onuki et al, 1999) .
Microdissection and DNA extraction
Serial 5 mm sections were cut from archival, formalinfixed, paraffin-embedded tissue. All slides were stained with haematoxylin-eosin, and one of the slides was cover slipped. The cover-slipped slide was used as a guide to localize regions of interest for microdissection in the non-cover-slipped slides. Microdissection and DNA extraction were performed as previously described from sections of each sample. Cells from lymph nodes without metastasis or histologically normal lung were used as a source of constitutional DNA from each case. After DNA extraction, 5 µl of the proteinase K digested samples, containing DNA from at least 100 cells, were used for each PCR-based analysis.
Polymorphic DNA markers and PCR-LOH analysis
To evaluate LOH and MA in neuroendocrine tumour as lowmalignant lesions of SCLC, we used primers flanking 16 di-, tetra-and multinucleotide microsatellite repeat polymorphisms located at the chromosomal locations 10p15 and all the data were compared with those from 3p14.1-21.3. The microsatellite markers and the chromosomal regions analysed were as follows: 10p15 (D10S249, D10S594, D10S602, D10S591, D10S1713, D10S189, D10S1751, D10S1691, AFM154YB4, CHCL.84C03, WI-5574, D10S1779, D10S226, D10S1728, D10S1649, D10S1712, D10S1720, CHCL.117B02, WI-600, D10S547) and 3p14.1-21.3 (D3S1029, D3S1478, KI.CA, D3S1573, ITIH-1, D3S1447, D3S1766). The primer sequences used for LOH studies were obtained from the Genome Database. For all samples, multiplex PCR (up to 8 primers) was performed in the first amplification, followed by uniplex PCR for individual microsatellite markers as previously described. LOH was recognized by visual detection of complete absence of upper or lower allele. MAs were identified by a shift in size of one or both parental alleles compared to constitutional DNA (from normal cells) from the same individual. In the multiplex PCR, 8 markers were amplified in the same reaction using extracted DNA from at least 100 microdissected nuclei. Volumes of 50 µl were used for each multiplex reaction, containing 20 mM TRIS (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 400 mM of each deoxynucleoside triphosphate (dATP, dCTP, dGTP, dTTP), 0.5 µM of each forward and reverse primer, and 3.5 units of AmpliTaq Gold (Perkin Elmer, Branchburg, NJ). The first PCR product was then diluted 1:10 in double distilled sterile water. The second PCR reaction was performed in 10 µl reaction volume containing 20 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 100 mM of each deoxynucleoside triphosphate, 0.5 µM of forward and reverse primer, 0.25 unit of AmpliTaq polymerase (Gibco-BRL, Alameda, CA), 0.25 µl of (α-32 P) dCTP (3000 Ci mol -1 , 10 mCi ml -1 ), (Amersham Life Sciences, Arlington Heights, IL), and 2 µl of diluted first PCR product. In both PCR reactions, a 'touch-down' PCR method was performed. Briefly, after initial denaturation at 94˚C for 4 to 8 min, 11 cycles each consisting of denaturation at 95˚C for 20 s, annealing at 65-56˚C for 55 s and extension at 72˚C for 20 s were performed, followed by an additional 24 cycles which included denaturation at 90˚C for 20 s, annealing at 55˚C for 20 s and extension at 72˚C for 20 s. Then, a 5 µl aliquot of each second PCR reaction was diluted 1:4 with loading buffer, heat denatured, and separated by electrophoresis on a denaturing 6% polyacrylamide gel containing 7 M urea. A water blank control was included in all gels. LOH was scored in informative cases by visual detection of complete absence of the one allele.
hTR expression in situ hybridization (ISH)
To compare the result of LOH analysis using STS markers with hTR expression, we performed cRNA in situ hybridization in the low-malignant grade of lung tumour (TCs and ACs).
Preparation and prehybridization of tissue sections for ISH
Paraffin-embedded (5 mm) tissue sections of 6 tumour-negative and 4 tumour-positive lymph nodes were cut onto Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA, USA). The sections were deparaffinized, rehydrated in phosphate-buffered saline (PBS), and treated with proteinase K (20 mg ml -1 ) in 50 mM Tris-HCL (pH 7.5), 5 mM EDTA for 20 min at room temperature. After rinsing for 5 min in PBS, sections were postfixed in 4% paraformaldehyde/PBS, rinsed in water, and acetylated in freshly prepared 0.25% acetic anhydride/0.1 M triethanolamine for 10 min. The slides were dehydrated in gradually increasing concentrations of ethanol prior to hybridization.
Probe preparation for ISH
The plasmid pGEM-5Zf(+) (Promega Corp., Madison, WI, USA) containing a human telomerase RNA (hTR) complementary DNA (560 nucleotides), obtained from Geron Corp, Menlo Park, CA, USA, was used as a template to generate sense and antisense probe. [
35 S]UTP-labelled single-stranded RNA probes were synthesized according to manufacturer's (Ambion, Inc, Austin, TX, USA) conditions. Transcripts were alkali hydrolysed to generate probes with an average length of 200 nucleotides for efficient hybridization, purified using G-50 column (Boehringer Mannheim Corp, Indianapolis, IN, USA), and precipitated in ethanol. The probes were resuspended in 30 µl of 100 mM dithiothritol. The specific activity of the radiolabelled probes, aliquoted and stored at -80˚C until use, was approximately 3 × 10 7 cpm mg -1 template DNA.
Hybridization and washing procedures
Sections were hybridized overnight at 52˚C in 50% deionized formamide, 0.3 M NaCl, 20 mM TRIS-HCl (pH 7.5), 5 mM EDTA, 10 mM NaH 2 PO4 (pH 8.0), 10% dextran sulfate, 1 × Denhardt's, 500 mg ml -1 total yeast RNA, 10 mM dithiothritol, and 50000 cpm ml -1 35 S-labelled cRNA probe. The tissue was subjected to stringent washing at 50˚C in 5 × SSC, 10 mM dithiothritol for 30 min, at 65˚C in 50% formamide, 2 × SSC, 10 mM DTT for 20 min and washed twice at 37˚C in 0.4 M NaCl, 10 mM Tris-HCl (pH 7.5), 5 mM EDTA for 10 min before treatment with 20 mg ml -1 RNase A at 37˚C for 30 min. Following washes in 2 × SSC and 0.1 × SSC for 10 min at 37˚C, the slides were dehydrated and dipped in Kodak NTB-2 nuclear track emulsion and exposed for 3 wk in light tight boxes with dessicant at 4˚C. The microautradiographs were developed in Kodak Dektol developer (3.5 min), washed in water (20 s), fixed in Kodak fixer (7 min), rinsed in water, counterstained in haematoxylin and eosin. ISH for hTR was performed as described previously (Yashima et al, 1997) . To confirm the presence of intact RNA, replicate slides from each sample utilized for hTR expression were also tested for expression of a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The Xba/HindIII fragment from the GAPDH cDNA in pBR322 obtained from the American Type Culture Collection, Rockville, MD, was subcloned into pBluescript. Intense GAPDH hybridization signals were present in all sections studied.
hTR expression was scored as follows: weak -faint expression, detected by brightfield examination at high magnification, but which was detected at low magnification by darkfield examination; moderate -expression readily recognized by brightfield examination at low magnification; high -expression at a level considerably greater than those present in normal. We estimated each level of hTR expression as positive because even weakly positive signals are visually distinguishable, compared with negative ones in ISH.
RESULTS
Comparison of hTR expression with LOH analyses
To confirm that the region of interest was between markers D10S226 and D10S547 on 10p15.1, and to narrow this region, we performed LOH analysis by PCR in pulmonary low-malignant tumours including low-grade typical carcinoid (TC) and the more malignant atypical carcinoids (AC) (Travis et al, 1998) . Because there were no significant differences between TC and AC, we combined the data. LOH with one or more markers was present in 53% (9/17) of telomerase positive in our samples. Also we compared the data from 10p15 with those from 3p14.2-21.3 because we and others have reported a possibility that a telomerase repressor may be harboured at 3p as well. Represented in Figure 1 , in 21 samples of TCs and ACs, 6 LOHs, 2 microsatellite alterations (MAs), 4 not informative cases, and 10 cases without LOH were observed with marker D10S1728, and 2 LOHs were observed with other sequence tagged site (STS) markers on 10p15. All the LOHs and 1 MA concorded with the expression of hTR ISH. hTR expression and LOH in 10p15.1 showed a high concordance (13 out of 15 samples: 87%). On the other hand, 9 out of 17 (53%) in 3p21.2-21.3 and 6 out of 10 (60%) in 3p14.2-21.2 showed a little lower concordance with hTR expression than that of 10p15.1 (Figure 2) . Furthermore, comparison between LOH and hTR expression with only a marker D10S1728 revealed 81% of concordance in lung neuroendocrine (NE) tumours. In smallcell lung carcinomas (SCLCs), 15 out of 18 (83.3%) in 10p15.1 (D10S226, D10S1728, D10S1649, D10S1712, and D10S1720) as markers which are located within zero genetic distance) showed LOH and 3 out of 18 showed MAs. In large cell neuroendocrine carcinomas (LCNECs), 14 out of 15 (93.3%) with the same markers of 10p15 showed LOH and 1 out of 15 showed MA. Each level (weak, moderate and high signals) of hTR expression did not significantly correlate with the grades of carcinoid tumours.
Additionally, LOH analysis using D10S1728 which showed the highest concordance as the hot spot was performed in 132 lung cancer cell lines but no homozygous deletions were recognized.
DISCUSSION
Telomerase activity is detected in most human cancer tissues and immortalized cells and is almost universally required for the longterm growth of cancer cells. We and others previously reported that the activation of telomerase is strongly associated with the development of human hepatocellular carcinomas (HCCs) (Miura et al, 1997) . Escape from the cellular senescence programme is a showed high concordance (81%) with hTR expression than any other markers rate-limiting step during carcinogenesis (Norwood et al, 1974; Sager, 1991; Campisi, 1997; Chiu and Harley 1997; Pereira-Smith et al, 1998) . We have recently reported the presence of another senescence-inducing gene (Sasaki et al, 1994; Ohmura et al, 1995; Tanaka et al, 1998) that also functions as a telomerase repressor on human chromosome 3p (Holt et al, 1997; Meyerson et al, 1997; Nakamura et al, 1997 Nakamura et al, , 1998 . In the case, telomerase repression was due to down-regulation of the gene encoding the catalytic subunit of human telomerase (hEST2/hTERT) . In other cases, telomerase repression during cell differentiation was associated with down-regulation of the RNA component of telomerase (hTR) (Bickenback et al, 1998) . Given that LOH at either 3p or 10p was associated with telomerase activation (Steenbergen et al, 1996) , the 2 possible telomerase-repressor genes on 3p and 10p may be part of the same cascade of telomerase regulation. Alternatively, as reported in this study, the repressors may have independent, but synergistic functions to regulate the repression pathway of telomerase. Further studies will be needed to determine the molecular basis for telomerase repression by the 10p gene and its functional relationship to the 3p gene. Nonetheless, our results provide new insights into the mechanism of telomerase regulation by demonstrating that the repression of telomerase activity in normal human somatic cells is under multifactorial control, which involves at least 2 telomerase-repressor genes (Oshimura and Barrett, 1997) .
Relatively frequent alterations and deletions of chromosome 10p have been identified in many human tumours including glioblastoma multiforme (GBM) (Bigner et al, 1990; Steck et al, 1995; Tsuda et al, 1995; Voesten et al, 1997; Kon et al, 1998) , malignant melanoma (MM) (Isshiki et al, 1993) , and meningioma (Rempel et al, 1993) . Since human glioblastoma hybrid cells containing an entire chromosome 10 or major portions of chromosome 10 exhibited a suppression in their ability to grow anchorage independently and to form tumours in nude mouse (Pershouse et al, 1993) , the presence of suppressor gene in chromosome 10p has been suggested. In high-grade astrocytomas such as glioblatoma multiforme (GBM), 3 distinct regions of frequent chromosome 10 deletion have been identified, and one of them is the distal half of the short arm defined by markers D10S33, D10S28, and D10S34 (Karlbom et al, 1993; Steck et al, 1995) . This indicates that several distinct tumour suppressor genes may be present on chromosome 10 and may contribute to the progression of malignant tumours. Further investigation has also indicated that LOH on 10p was frequently identified in GBM and MM, and 10p as well as 3p encodes genes involved in telomerase regulation (Steenbergen et al, 1996) . 10p15 was structurally altered in malignant melanoma (10pter-p13) and GBM (10pter-p14) and is included in a candidate of locus (10pter-q11) (Sanchez et al, 1996) has pointed out that a telomerase repressor may exist. Frequent LOH on 10p has not been reported in human HCCs. This may suggest that the telomerase-repressor/senescence-inducing gene on 10p is implicated in development of only a fraction of HCCs or fewer STS markers in chromosome 10p than those in other chromosomes have kept the detection of LOH away from us. Actually, we detected 67% of LOH (4/6) at D10S1649 in HCCs (unpublished) . Conversely, it is plausible that the 10p15.1 gene is involved in human cancers other than HCC, such as neuroendocrine lung tumour (we detected 56% of LOH (5/9) at D10S1728 and 63% of LOH (7/11) at D10S1712 in lung squamous cell carcinoma). Of interest is whether a putative tumour suppressor gene(s) on 10p for gliomas and oesophageal cancers is identical to the telomerase-repressor/senescence-inducing gene described in this study. As an additional experiment, we performed allelic analyses in microdissected lung tumours in order to confirm whether the hot spot from deletion mapping by MMCT, RMF, and LOH analyses using STS markers can be still identified as a hot spot. Interestingly, as these hot spots showed a higher concordance with the detection of telomerase activity in lung tumours than any part of 3p, though it is true that 3p still shows high concordance (71%) with telomerase activity, a series of our study may indicate that the gene lying around the region of our interest may be able to act as a repressor of hTR and/or transcriptional repressor of hTERT (Nakamura et al, 1997; Ulaner et al, 1998) . (cM) Figure 3 The summary of this series of mapping. We identified a hot spot (polymorphic marker D10S1728 at 10p15.1) as a functional region whose allelic loss correlates with up-regulation of telomerase activity in lung carcinoids
